• en
  • it
  • de
  • UPDATE 4: IMPACT OF THE CURRENT COVID-19 OUTBREAK ON INDIAN PRODUCTION SITES

    PharmaZell Group is very conscious of our important role and duty in delivering APIs to our customers and being an active part in maintaining the health system running.

    Up to now, the PharmaZell Group has been able to limit the impact of the Corona Virus outbreak (COVID-19) to the largest extent.

    Despite the fact that Indian authorities have classified our API manufacturing units in Chennai and Vizag as critical for the health system, it has become difficult for us to operate them under the nationwide lockdown announced by the Indian authorities earlier this week. Namely in- and out-bound logistics are severely impacted.

    At this moment in time, we expect some disruptions of planned shipments and possible further spill-over effects to our European operations, due to some inter-site dependencies. Negative impacts, durations and mitigations strategies are assessed permanently.

    If you were to be affected by such disruptions or delays, your responsible account manager is going to reach out to you to discuss and find possibilities to limit such negative impacts for you.

    Please be assured that our commitment to delivering APIs to our customers and being an active part in maintaining the health system running is unabated.

    Thank you for your understanding and co-operation in these, for all of us, challenging times.

    2-April-2020

    search for what
    Generic filters
    Exact matches only